Semax

Quick Facts

Introduction

Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment of adrenocorticotropic hormone, modified so that it retains neurotropic activity while losing the hormonal (corticotropic) effects of the parent molecule. It is one of the most studied compounds in the Russian neuropeptide research tradition and anchors a small family of short, regulatory peptides investigated for cognition. Within that family it is most often examined alongside Selank, an anxiolytic-leaning analogue developed in the same research lineage.

The conceptual appeal of Semax research is that a very short peptide appears to influence the expression of neurotrophic factors — particularly brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) — which sit upstream of synaptic plasticity and neuronal survival. Because it is studied predominantly via intranasal administration, it is also frequently referenced in the practical context of nasal-delivery peptides rather than injectable protocols.

This profile covers what Semax is, the structural extension that gives it metabolic stability, its proposed neurotrophic and neurotransmitter mechanisms, the cognitive and neuroprotective research it appears in, and how it compares with related nootropic peptides such as Selank and P-21. Related compounds are catalogued in the peptide database.

What is Semax?

Semax is built from the ACTH(4-7) core sequence (Met-Glu-His-Phe) — the region of adrenocorticotropic hormone responsible for its behavioral and neurotropic activity rather than its steroidogenic activity — extended at the C-terminus with the tripeptide Pro-Gly-Pro. This gives the full sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP).

The Pro-Gly-Pro addition is the defining design feature. Native ACTH fragments are degraded almost immediately by serum and tissue peptidases, which limits their usefulness as research tools. The terminal proline residues sharply slow enzymatic cleavage, extending the functional window long enough for the peptide to exert measurable central effects after intranasal delivery. A naturally occurring breakdown product of this extension, the Pro-Gly-Pro fragment itself, has been studied as a biologically active metabolite in its own right.

Molecular and structural characteristics

Structurally, Semax preserves the histidine and phenylalanine residues thought to be critical for the neurotropic activity of the melanocortin fragment while discarding the residues associated with adrenal stimulation. The result is a compact, water-soluble peptide that is studied for central nervous system effects without measurable activation of the hypothalamic–pituitary–adrenal axis.

Mechanism of action

The most consistently reported mechanism in the Semax literature is upregulation of neurotrophic factors. Preclinical models have associated Semax exposure with rapid increases in the expression of BDNF and its receptor TrkB, as well as NGF, in regions such as the hippocampus and basal forebrain. Because BDNF/TrkB signaling supports synaptic plasticity, long-term potentiation, and neuronal survival, this pathway is the leading mechanistic explanation offered for the cognitive endpoints studied with the peptide.

Semax is also studied for effects on monoaminergic systems, with reports of modulated dopaminergic and serotonergic tone and altered activity of the brain's endogenous regulatory peptides, including the enkephalin and BDNF systems acting in concert. Some research additionally describes inhibition of enzymes that degrade enkephalins, which would prolong endogenous opioid-peptide signaling — one proposed contributor to its reported effects on attention and stress resilience.

In ischemia and hypoxia models, Semax has been associated with neuroprotective changes in gene expression, including modulation of inflammatory and vascular pathways and reduced markers of oxidative damage. As a melanocortin-lineage peptide it engages this biology without the corticotropic activity of full ACTH, which is the conceptual distinction researchers emphasize.

• Increased expression of BDNF and NGF and their downstream signaling.
• Modulation of dopaminergic and serotonergic neurotransmission.
• Reported inhibition of enkephalin-degrading peptidases.
• Neuroprotective gene-expression changes in ischemia/hypoxia models.
• Melanocortin-lineage activity without HPA-axis stimulation.

Cognitive and attentional research

The endpoint most associated with Semax is attention and cognitive performance under load. Preclinical and small clinical studies in the Russian literature have examined effects on learning, memory consolidation, and concentration, often framing the peptide as an adaptogenic regulator that supports performance during mental fatigue or stress rather than as a stimulant. The proposed link to BDNF expression provides a plausible substrate for these observations.

Because the peptide is studied largely through intranasal delivery, much of its research interest overlaps with practical questions about nose-to-brain transport. It sits in the same conceptual conversation as other nootropic peptides studied for focus and cognition, including Selank, which is investigated more for anxiolytic endpoints, and the angiotensin-IV analogue Dihexa, which is studied for synaptogenesis.

Neuroprotection research

A substantial portion of the Semax evidence base concerns cerebral ischemia. In rodent stroke models, Semax administration has been associated with reduced infarct-related damage and changes in the expression of genes involved in inflammation, vascular function, and neuronal survival. These observations underpin the peptide's long-standing study in the context of acute and recovery-phase neuroprotection within its country of origin.

Comparison: Semax vs Selank vs P-21

Semax is most often compared with Selank, a tuftsin-derived peptide from the same research lineage studied for anxiolytic endpoints, and with P-21, a neurotrophic-factor mimetic studied for neurogenesis. All three are short peptides investigated for central nervous system effects, but they differ in origin and emphasis.

Researchers sometimes study Semax and Selank together because their proposed mechanisms — neurotrophic upregulation versus GABAergic modulation — are framed as complementary. Full entries for each are in the peptide database.

Half-life and pharmacokinetic considerations

Semax is characterized by a short circulating half-life measured in minutes, a consequence of peptidase activity even with the protective Pro-Gly-Pro extension. The terminal prolines slow degradation enough to permit central effects but do not produce a long systemic exposure. This is why the peptide is studied predominantly via the intranasal route, which is examined as a way to favor direct nose-to-brain transport and reduce reliance on systemic distribution.

An interpretive nuance in Semax research is that its metabolites remain active. The Pro-Gly-Pro fragment generated during degradation has its own reported biological activity, so the functional duration of effect can outlast the parent peptide's measurable plasma concentration. Researchers therefore treat simple half-life figures as an incomplete description of the compound's activity.

Reconstitution and handling considerations

Lyophilized Semax is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken. The reconstituted solution should be clear and colorless; cloudiness or particulates indicate it should be discarded. Because the peptide is frequently prepared for intranasal research use, concentrations are chosen so that small, reproducible volumes deliver the intended amount.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear and colorless before use.
• Protect from light and excess warmth.
• Avoid repeated freeze–thaw cycles of reconstituted material.

Storage considerations

Lyophilized Semax is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled. Nasal preparations in particular benefit from cold storage and protection from light.

Research limitations

Semax has an unusually long history of study, but much of its evidence base comes from preclinical models and from clinical research conducted within a single national research tradition, with limited large-scale independent replication outside it. Reported effects are dose-, route-, and design-dependent, and the relationship between its short plasma half-life and its longer functional effects remains an active research question. It is described here strictly for research reference.

• Much evidence is preclinical or from a single research tradition.
• Independent large-scale replication is limited.
• Reported effects are dose-, route-, and design-dependent.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006.
2. Shadrina M, Kolomin T, Agapova T, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience. 2010.
3. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia. Molecular Biology (Mosk). 2014.